SUZHOU, China, Dec. 25, 2024 /PRNewswire/ -- In November 2024, Higer New V Series buses officially launched in the Philippines, this batch of electric buses was the first batch of new energy buses introduced by the Philippines and put into commercial operation. And it has aroused extensive attentions and heated discussions from the Philippines local government, media and people.
Higer New V Series products were launched globally in March 2024, and then made a stunning debut at the Higer Global Partners Conference. The New V-series products with a new shape and a new platform are committed to creating new classic models with high quality, high safety and high intelligence.
In 3 years, more than 1000 people participated in the process of R&D, a one-time investment of more than 100 million yuan was made in the R&D and manufacturing of key components, equipment, tooling, molds, inspection tools, verification of components and vehicle, achieving comprehensive innovation, realizing a significant improvement in product quality and reliability, maintenance convenience and customer experience. Measuring from 8 to 13 meters in length, they can be powered by fossil fuels, electricity, hydrogen, etc. and are readily adaptable for the tourist transportation market, urban public transportation market, etc. The luggage compartment volume is 21.6% greater than similar products, the seating space is 50mm larger, and the middle aisle is 30mm wider. The overall component universality rate was greatly improved by the platform, modular, and universal design concept, and the number of component types decreased by 58%.
It is worth mentioning that Higer is committed to creating a technological experience, redefining the domain-centralized electronic and electrical architecture, and Higer launched the industry's first mass-produced intelligent cabin. It will help the driver concentrate on driving. The new model provides a mobile phone control interface, drivers and tour guides can control lighting, multimedia, air conditioning, etc. through app. In addition, the intelligent cabin can be customized according to the operational needs of the transport company, realizing intelligent dispatching, intelligent charging, intelligent maintenance, AI interaction, and human-computer interaction.
So far, Higer new V series coaches have already received orders from more than 20 countries like Italy, Qatar, UAE, Saudi Arabia, Algeria and etc., showing a fast rising popularity in the international market.
Higer new V series are committed to providing customers with new "classic models" with better quality, higher efficiency, achieving sustainable development and exploring more possibilities.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Higer New V Series, Leading Bus New Trend
Higer New V Series, Leading Bus New Trend
HEIDELBERG, Germany, Dec. 25, 2024 /PRNewswire/ -- European Wellness Biomedical Group (EWBG) has launched a new research initiative focused on Klotho, a protein with transformative potential in longevity medicine. Led by Professor Dr. Mike Chan, this project will explore Klotho's role in combating age-related diseases and its ability to regenerate critical organs, including the brain, kidneys, and heart.
Klotho, identified in 1997, is emerging as a key protein in longevity and regenerative medicine. It plays a pivotal role in regulating oxidative stress, mineral metabolism, and inflammation. The research will investigate how boosting Klotho levels could help address chronic conditions like neurodegenerative diseases, kidney failure, and heart disease, ultimately improving healthspan and extending lifespan.
"Klotho represents the next frontier in longevity medicine," said Professor Mike Chan, Chief Scientist at EWBG. "Our research aims to understand how Klotho affects aging and how we can use it to treat chronic diseases that have long been associated with aging."
Research Focus Areas
The new initiative will focus on three primary research areas:
This research builds on existing collaborations at EWBG, where leading scientists focus on advancing Klotho-based therapies for regenerative health.
Klotho: A Potential Breakthrough in Longevity Medicine
Klotho is gaining attention for its ability to regenerate tissues and reverse damage caused by age-related diseases. Unlike NAD+, which primarily enhances cellular metabolism and energy production, Klotho offers a broader range of therapeutic applications, including tissue regeneration, cognitive function improvement, and cardiovascular health.
As we age, Klotho levels naturally decline, leading to conditions such as cognitive decline, heart disease, and kidney failure. Research suggests that restoring Klotho levels can reverse the effects of oxidative stress, inflammation, and cellular senescence, offering new treatment possibilities for a range of age-related diseases.
Professor Mike Chan: Leading the Charge in Klotho Research
Professor Mike Chan, a leading expert in stem cell therapy and longevity medicine, is spearheading this groundbreaking initiative at EWBG. His extensive experience in bio-regenerative medicine positions him as a key figure in exploring Klotho's potential to revolutionize the treatment of age-related diseases. Through FCTI, a subsidiary of EWBG, Professor Chan and his team are developing therapies that combine stem cell technology and Klotho proteins to stimulate tissue regeneration in the brain, kidneys, and heart.
"By harnessing Klotho's regenerative properties, we hope to address chronic conditions that were previously untreatable," said Professor Chan. "Our ultimate goal is to improve quality of life and provide lasting solutions for those affected by aging-related diseases."
The Future of Klotho in Longevity Medicine
The future of Klotho-based therapies looks promising, with Professor Mike Chan and EWBG at the forefront of this innovative field. As more research is conducted, Klotho is expected to play a pivotal role in advancing longevity medicine, offering a new approach to treating aging and chronic diseases. The potential applications of Klotho are vast, from neurodegenerative disease treatment to kidney regeneration and cardiovascular health.
With strong research partnerships, significant funding, and ongoing clinical trials, Klotho is poised to become a cornerstone of longevity medicine, transforming how we approach aging and disease. Professor Mike Chan's leadership ensures that this promising protein will soon offer new hope to those seeking longer, healthier lives.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
European Wellness Biomedical Group Announces New Klotho Research Initiative Led by Prof. Mike Chan
